PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
12.91M
Better than RNAZ's estimated revenue of 500.00K.
-2.58M
Worse than RNAZ's estimated ebitda of 0.
-0.93
Better than RNAZ's estimated eps of -8.96.
-21.85M
Worse than RNAZ's estimated net income of -3.19M.
-2.58M
Worse than RNAZ's estimated ebit of 0.
478.53M
Worse than RNAZ's estimated sg&a expense of 0.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
-50.53%
Worse than RNAZ's revenue growth rate of 0.00%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Worse than RNAZ's ebitda margin of 100.00%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Worse than RNAZ's ebit margin of 100.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
100.00%
Equal to RNAZ's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Better than RNAZ's receivables as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Better than RNAZ's inventories as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Equal to RNAZ's payables as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
-29.43%
Better than RNAZ's capex as percentage of revenue of 0.00%.
4.99%
Better than RNAZ's weighted average cost of capital (wacc) of 12.20%.
5.02%
Better than RNAZ's cost of equity of 11.27%.
4.08%
Better than RNAZ's cost of debt of 70.02%.
-0.23
Better than RNAZ's beta of 1.53.
30.07M
Worse than RNAZ's diluted shares outstanding of 356.12K.
1.57M
Worse than RNAZ's total debt of 38.29K.
49.31M
Better than RNAZ's total equity of 2.39M.
50.89M
Better than RNAZ's total capital of 2.42M.
3.09%
Worse than RNAZ's debt weighting of 1.58%.
96.91%
Worse than RNAZ's equity weighting of 98.42%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
2.00%
Equal to RNAZ's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than RNAZ's net debt of -5.77M.
71.33M
Better than RNAZ's equity value of 5.77M.
2.37
Worse than RNAZ's equity value per share of 16.21.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.